目的：探讨Ki67表达与乳腺癌新辅助化疗疗效的关系。方法选取本院2010年1月~2014年1月收治入院的接受新辅助化疗的乳腺癌患者80例,根据Ki67的阳性细胞比例,将患者分为高表达组(n=57)和低表达组(n=23)；根据Ki67表达下降水平,将患者分为明显下降组(n=66)、轻度下降组(n=14)。应用Miler and Payne(MP)治疗反应评价系统评价病理学疗效。结果MP治疗反应评价结果院1级8例,2级16例,3级49例,4级4例,5级3例。高表达组的病理有效率显著高于低表达组(字2=6.218,P<0.05),明显下降组显著高于轻度下降组(字2=10.083,P<0.05)。结论 Ki67可作为预测和评估乳腺癌新辅助化疗疗效的生物学指标。%Objective To explore the relationship between Ki67 expression and curative effect of neoadjuvant chemotherapy for breast cancer. Methods From January 2010 to January 2014,80 patients with breast cancer accepted neoadjuvant chemotherapy and treated in our hospital were selected.Patients were divided into high expression group (n=57) and low expression group (n=23) according to positive cell proportion of Ki67;patients were divided into de-creased obviously group (n=64) and decreased slightly group (n=16) according to decreased level of Ki67 expression. Miler and Payne (MP)treatment reaction system was used to evaluate the curative effect of pathology. Results Evalua-tion result of MP treatment reaction:the number of cases in grade 1,2,3,4,and 5 was 8,16,49,4,and 3 respectively.The ef-fective rate of pathology in high expression group was obviously higher than that of low expression group (χ²=6.218,P<0.05) and the effective rate of pathology in decreased obviously group was obviously higher than that of decreased slightly group (χ²=10.083,P<0.05). Conclusion Ki67 can be considered as a biological indicator in predicting and eval-uating the curative effect of neoadjuvant chemotherapy on breast cancer.
展开▼
